4
Background
Vaccination is an important tool for controlling the COVID-19 pandemic. COVID-19 vaccines are safe and
effective at reducing the risk of severe infections, being hospitalized, and dying from COVID-19.
Approximately 70% of the Washington population ages 6 months and older has completed the primary
COVID-19 vaccine series and over half of the population has received at least one booster dose (shot).
Unvaccinated Washingtonians are at risk of serious outcomes such as being hospitalized and dying due
to COVID-19. Because vaccination rates vary across the state between different age and demographic
groups, some populations may be more vulnerable to these serious outcomes.
Although COVID-19 vaccines work well to protect against severe infections, being hospitalized, and
dying from COVID-19, some people who are vaccinated with the primary series or who have received a
booster dose will still get COVID-19 if they are exposed to the virus. As more individuals become
vaccinated it is natural to see more vaccinated individuals get COVID-19, and even be hospitalized or die
from COVID-19. However, because people who have completed the primary series and received at least
one booster dose are much less likely to be hospitalized or die compared to those who are
unvaccinated, increasing vaccination rates remains important to protect Washingtonians from severe
COVID-19 infections and save lives.
This report shows the impact of vaccination on COVID-19 in Washington by describing rates of COVID-19
hospitalizations and deaths among people with different vaccination statuses. This report breaks
vaccination status into three categories:
• Unvaccinated: those who have not received any dose of an authorized COVID-19 vaccine.
• Completed primary series: those who have reached two weeks after receiving the final
recommended dose of the primary series of an authorized COVID-19 vaccine.
• Boosted: those who have reached two weeks after receiving at least one booster dose or
additional dose of a monovalent COVID-19 vaccine. Individuals are not considered to have full
protection from the monovalent booster dose until two weeks have passed since receiving the
dose because of the time required for the body to build protection. COVID-19 vaccines
categorized as “monovalent” are the initial COVID-19 vaccines that were approved by the Food
and Drug Administration (FDA). Doses used for the primary series are monovalent vaccines.
These are different from the new booster doses authorized by the FDA for use beginning
September 1, 2022, which are referred to as “bivalent” vaccines. Data about doses of bivalent
boosters are not included in this report.
PLEASE NOTE:
• Information about bivalent boosters is not included in this report in order to avoid confusing the
impact of the bivalent boosters with the impact of the monovalent boosters. Individuals who
received a bivalent booster after August 31, 2022 are removed from the analyses presented
here. Information about the impact of bivalent boosters will be included in future iterations of
this report once a sufficient percentage of the Washington population has received the booster.
• Immunocompromised individuals are eligible for an additional dose following the primary series
before being eligible for a booster dose. Because DOH has very limited data about whether
someone is immunocompromised, all doses received after the primary series is completed are
categorized as “booster doses”.